Decoy Therapeutics targets second-half 2027 trial application for pan-coronavirus candidate
DCOY•Decoy Therapeutics expects to file a CTA or IND application in the second half of 2027 to begin Phase 1 pan-coronavirus trials. Cash totaled $8.1 million at September 30, 2026, including approximately $2.5 million in restricted Gates Foundation grant funding.
1. Development plans
Decoy Therapeutics expects to file a CTA or IND application in the second half of 2027 to begin Phase 1 trials of its pan-coronavirus candidate. An optimized lead showed potential for once-weekly dosing in preclinical studies, compared with daily dosing for earlier candidates. The company is pursuing non-dilutive funding applications and strategic collaborations to support development, including an exploratory pan-filovirus program.
2. Cash position
Cash totaled $8.1 million at September 30, 2026, including approximately $2.5 million in restricted Gates Foundation grant funding.
